Journal articleCancer Lett2026

A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.

DOI 10.1016/j.canlet.2025.218233 ↗ OpenAlex, retrieved 5 November 2026

Journal: Cancer Lett
Published: 23 December 2025
Citations: 1
Type: Article
License: cc by

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try